试验组: TT 对照组: NTT

Intervention: TT Comparison: NTT

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect (95% CI)

No of Participants (studies)

Quality of the evidence (GRADE)

Comments

Assumed risk

Corresponding risk

NTT

TT

AL VAS

Study population

OR 0.66 (0.46 to 0.94)

2748 (9 studies)

♁♁♁♁ high

109 per 1000

74 per 1000 (53 to 103)

Moderate

107 per 1000

73 per 1000 (52 to 101)

Preoperative chemotherapy or radiotherapy VAS

Study population

OR 0.7 (0.48 to 1.02)

2547 (8 studies)

♁♁♁♁ high

106 per 1000

77 per 1000 (54 to 108)

Moderate

105 per 1000

76 per 1000 (53 to 107)

Mortality VAS

Study population

OR 0.74 (0.16 to 3.36)

1678 (5 studies)

♁♁♁♁ high

3 per 1000

2 per 1000 (1 to 11)

Moderate

0 per 1000

0 per 1000 (0 to 0)

Reoperation VAS

Study population

OR 0.55 (0.25 to 1.22)

1602 (6 studies)

♁♁♁♁ high

73 per 1000

41 per 1000 (19 to 88)

Moderate

80 per 1000

46 per 1000 (21 to 96)

Length of hospital stays VAS

The mean length of hospital stays in the intervention groups was 2.12 lower (3.77 to 0.47 lower)

1136 (4 studies)

♁♁♁♁ high

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio;

GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.